Search

Roche Holding AG

Closed

SectorHealthcare

283.2 -0.07

Overview

Share price change

24h

Current

Min

279.6

Max

286

Key metrics

By Trading Economics

Income

1.7B

3.7B

Sales

-15B

16B

P/E

Sector Avg

25.123

37.461

Dividend yield

3.28

Profit margin

23.266

Employees

103,249

EBITDA

547M

6.5B

Dividends

By Dow Jones

Dividend yield

Sector Avg

3.28%

2.33%

Market Stats

By TradingEconomics

Market Cap

22B

227B

Previous open

283.27

Previous close

283.2

News Sentiment

By Acuity

40%

60%

139 / 371 Healthcare

Roche Holding AG Chart

Past performance is not a reliable indicator of future results.

Related News

23 Oct 2025, 09:32 UTC

Earnings

Roche Raises Full-Year Earnings Outlook as U.S. Drug-Pricing Talks Continue -- Update

23 Oct 2025, 05:54 UTC

Earnings

Roche Raises Full-Year Earnings Outlook

1 Oct 2025, 08:54 UTC

Major Market Movers

Pharma Stocks in Europe Jump After White House Unveils Drug-Buying Site

18 Sept 2025, 14:01 UTC

Acquisitions, Mergers, Takeovers

Roche to Buy Maker of Fatty Liver Treatment 89bio for Up to $3.5 Billion -- 2nd Update

18 Sept 2025, 10:05 UTC

Major Market Movers
Acquisitions, Mergers, Takeovers

89bio Shares Soar Premarket on Takeover by Roche

18 Sept 2025, 10:04 UTC

Acquisitions, Mergers, Takeovers

Roche to Buy Maker of Fatty Liver Treatment 89bio for Up to $3.5 Billion -- Update

18 Sept 2025, 05:37 UTC

Acquisitions, Mergers, Takeovers

Roche to Buy 89bio for Up to $3.5 Billion

23 Oct 2025, 09:19 UTC

Market Talk
Earnings

Roche's Sales Slow, But Drug Pipeline Could Support Long-Term Growth -- Market Talk

23 Oct 2025, 09:11 UTC

Market Talk
Earnings

Roche Sales Miss Driven by Underperformance of Key Drugs -- Market Talk

23 Oct 2025, 05:09 UTC

Earnings

Roche 3Q Sales Up 6% At CER

23 Oct 2025, 05:07 UTC

Earnings

Roche 3Q Sales CHF14.92B

23 Oct 2025, 05:07 UTC

Earnings

Analysts Had Seen 3Q Sales At CHF15.17B

23 Oct 2025, 05:07 UTC

Earnings

Roche See Core Earnings Per Share Growth In High-Single to Low-Double-Digit Range At CER

23 Oct 2025, 05:05 UTC

Earnings

Roche Expects An Increase In Group Sales In Mid-Single-Digit Range At CER

23 Oct 2025, 05:04 UTC

Earnings

Roche: Group Sales Up 7% At Constant Exchange Rates In First Nine Months

23 Oct 2025, 05:02 UTC

Earnings

Roche Had Seen High-Single-Digit 2025 Core Earnings Per Share Growth at CER

23 Oct 2025, 05:02 UTC

Earnings

Roche Had Seen Mid-Single-Digit 2025 Sales Growth At Constant Exchange Rates

23 Oct 2025, 05:02 UTC

Earnings

Roche 9-Mos CH45.9B

23 Oct 2025, 05:01 UTC

Earnings

Roche Raises 2025 View

1 Oct 2025, 20:33 UTC

Acquisitions, Mergers, Takeovers

Roche Begins Tender Offer for 89bio Pursuant to Previously Announced Merger Agreement

1 Oct 2025, 09:05 UTC

Hot Stocks

Stocks to Watch Wednesday: Nike, Lithium Americas, Arm, Occidental -- WSJ

18 Sept 2025, 14:12 UTC

Acquisitions, Mergers, Takeovers

89bio Stock Soars 86%. Why Roche Is Buying the Biopharma Company for $3.5 Billion. -- Barrons.com

18 Sept 2025, 07:37 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Roche's 89bio Acquisition Gives Its Drug Pipeline Potential Blockbuster -- Market Talk

18 Sept 2025, 05:09 UTC

Acquisitions, Mergers, Takeovers

89bio Says Deal Reflects Potential of Pegozafermin Drug Candidate

18 Sept 2025, 05:06 UTC

Acquisitions, Mergers, Takeovers

Roche: Deal Is Expected to Close in 4Q

18 Sept 2025, 05:06 UTC

Acquisitions, Mergers, Takeovers

Roche: Deal Enhanc Portfolio in Cardiovascular, Renal, Metabolic Diseases

18 Sept 2025, 05:05 UTC

Acquisitions, Mergers, Takeovers

Roche: MASH Is One of Most Prevalent Comorbidities of Obesity

18 Sept 2025, 05:05 UTC

Acquisitions, Mergers, Takeovers

Roche: 89bio Developing Potential Treatment for Metabolic Dysfunction-Associated Steatohepatitis

18 Sept 2025, 05:04 UTC

Acquisitions, Mergers, Takeovers

Roche to Buy 89bio for $14.50 a Share in Cash, Contingent Value Right of Up to $6 a Share

18 Sept 2025, 05:03 UTC

Acquisitions, Mergers, Takeovers

Roche: Total Deal Value Is Up to $3.5B

Roche Holding AG Forecast

Sentiment

By Acuity

139 / 371 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. It has strategic discovery collaboration with Flare Therapeutics Inc. proteomic and mass spectrometry platform and expertise to discover novel small molecules aimed at transcription factor targets in oncology. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.
help-icon Live chat